98%
921
2 minutes
20
'White Knight' is a popular climbing evergreen plant typically propagated through stem cuttings. However, this method is slow and inefficient, making it challenging to meet the rising market demand. In vitro propagation could enhance the multiplication of this cultivar. However, research on its in vitro propagation is limited. Therefore, the objective of the present study was to establish an efficient micropropagation technique to mass-produce 'White Knight' to meet the market demand. We investigate the impact of silver nanoparticles (Ag NPs) on the surface sterilization of 'White Knight' petioles, the role of plant growth regulators in adventitious shoot regeneration and shoot multiplication, and the effect of auxins on the rooting ability of 'White Knight' microshoots. There are few stages in plant micropropagation. The establishment of aseptic culture is the first and most important stage. For 'White Knight', aseptic petiole explants (100%) were obtained after treatment with 40 mg L Ag NPs for 60 min. This was followed by adventitious shoot induction, and the highest rate of adventitious shoot induction (52.6%) and the maximum shoot number (13.9 shoots per petiole) were achieved on Murashige and Skoog shoot multiplication B (MS-B) medium with 20 µM of 2-isopentenyl adenine (2-IP) and 5.0 µM of naphthalene acetic acid (NAA). The shoot multiplication stage was achieved with the highest number of shoots (34 shoots per shoot tip) with a length of 5.1 cm, which was obtained on MS-B medium with 5.0 µM 2-IP and 2.5 µM NAA. All the microshoots produced roots during the root induction stage with the maximum root number (8.2 roots per shoot), and the greatest plantlet height (9.1 cm) was achieved on half-strength Murashige and Skoog medium containing indole-3-butyric acid (10.0 μM). The rooted plantlets of 'White Knight' were transplanted into a substrate composed of 10% peat moss, 50% orchid stone, and 40% coconut husk chips and acclimatized in a greenhouse environment, achieving a survival rate of 100%. This micropropagation protocol can be used for the commercial production of 'White Knight'.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12157971 | PMC |
http://dx.doi.org/10.3390/plants14111714 | DOI Listing |
Circulation
September 2025
Department of Medicine, Stanford University, CA (D.J.M.).
Background: In ISCHEMIA (International Study of Comparative Health Effectiveness With Medical and Invasive Approaches), an invasive strategy demonstrated better health status outcomes than a conservative strategy in patients with chronic coronary disease (CCD). Some previous studies have shown greater health status benefits with coronary artery bypass grafting (CABG) than percutaneous coronary intervention (PCI). Whether the health status benefits of invasive management in ISCHEMIA were driven primarily by participants treated with CABG is unknown.
View Article and Find Full Text PDFLancet Oncol
September 2025
British Columbia Cancer Agency, Vancouver, BC, Canada.
Background: The role of metastasis-directed therapy (MDT) in castration-resistant prostate cancer (CRPC) remains unclear. Prostate Cancer Study 9 (PCS-9) aimed to evaluate the benefits of stereotactic body radiotherapy (SBRT) in addition to standard systemic therapy in patients with oligometastatic CRPC.
Methods: This open-label, randomised, phase 2 trial was conducted across 13 Canadian academic and community oncology centres.
Circ Cardiovasc Imaging
September 2025
Department of Cardiology, Boston Children's Hospital, Harvard Medical School, MA (F.S., A. Dionne, J.W.N., K.G.F.).
Background: 2D-speckle tracking echocardiography may help detect subclinical ventricular dysfunction, but data in multisystem inflammatory syndrome in children (MIS-C) are scarce. We investigated left ventricular (LV) strain parameters in MIS-C and their association with outcomes.
Methods: We performed an ambi-directional, 32-center cohort study on hospitalized MIS-C patients (March 2020-November 2021) with at least 1 echocardiogram read by the Core Lab.
Lancet
August 2025
Canadian VIGOUR Centre, University of Alberta, Edmonton, AB, Canada.
Background: Following completion of the VICTORIA trial, vericiguat was approved for the treatment of worsening heart failure with reduced ejection fraction (HFrEF) and received a class IIb recommendation in European and North American guidelines. The subsequent VICTOR trial evaluated the use of vericiguat in patients with HFrEF and no recent worsening. We aimed to assess the effect of vericiguat on clinical endpoints through pooled analyses of patient-level data from the VICTORIA and VICTOR trials.
View Article and Find Full Text PDFJAMA Intern Med
September 2025
Yale School of Public Health, New Haven, Connecticut.
Importance: Despite the large numbers of persons living with dementia, the best approach to providing dementia care is unknown.
Objective: To compare the effectiveness of health system dementia care (HSDC), community-based dementia care (CBDC), and usual care (UC) on person living with dementia and caregiver outcomes.
Design, Setting, And Participants: The Dementia Care Study (D-CARE) was a pragmatic, 18-month, 3-armed, assessor-blinded randomized clinical trial conducted from June 2019 through August 2023 at 4 clinical trial sites in North Carolina, Texas, and Pennsylvania.